Eric M Gibson

Array ( [id] => 18657743 [patent_doc_number] => 20230303697 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => Antiaging effect of Intradermal Administration of Immune Checkpoint Inhibitors [patent_app_type] => utility [patent_app_number] => 17/803947 [patent_app_country] => US [patent_app_date] => 2023-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12883 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 170 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17803947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18434351 [patent_doc_number] => 20230181645 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => METHOD TO IMPROVE CANCER VACCINES [patent_app_type] => utility [patent_app_number] => 18/065320 [patent_app_country] => US [patent_app_date] => 2022-12-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 61 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18065320 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18436066 [patent_doc_number] => 20230183360 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-15 [patent_title] => Use of Amivantamab to Treat Colorectal Cancer [patent_app_type] => utility [patent_app_number] => 18/077318 [patent_app_country] => US [patent_app_date] => 2022-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16894 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18077318 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468896 [patent_doc_number] => 20230203179 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => PHARMACEUTICAL COMPOSITION OF A HUMANIZED ANTI-CD40 ANTIBODY [patent_app_type] => utility [patent_app_number] => 18/051833 [patent_app_country] => US [patent_app_date] => 2022-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051833 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18336968 [patent_doc_number] => 20230128917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-27 [patent_title] => GENETICALLY ENGINEERED IMMUNE CELLS HAVING A DISRUPTED CD83 GENE [patent_app_type] => utility [patent_app_number] => 17/931701 [patent_app_country] => US [patent_app_date] => 2022-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26594 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17931701 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17640669 [patent_doc_number] => 20220168407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-02 [patent_title] => USE OF TUMOR-INDEPENDENT ANTIGENS IN IMMUNOTHERAPIES [patent_app_type] => utility [patent_app_number] => 17/519101 [patent_app_country] => US [patent_app_date] => 2021-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39914 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17519101 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17549409 [patent_doc_number] => 20220120750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => EXTRACELLULAR VESICLE BIOMARKERS FOR ENDOMETRIAL CANCER [patent_app_type] => utility [patent_app_number] => 17/503473 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5859 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17503473 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17385932 [patent_doc_number] => 20220033784 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => RECOMBINANT VACCINIA VIRUS [patent_app_type] => utility [patent_app_number] => 17/371206 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53300 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17371206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17297936 [patent_doc_number] => 20210393775 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => Daratumumab and Hyaluronidase for the Treatment of Multiple Myeloma [patent_app_type] => utility [patent_app_number] => 17/343150 [patent_app_country] => US [patent_app_date] => 2021-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23732 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17343150 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17095361 [patent_doc_number] => 20210283152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => METHOD FOR TREATMENT OF COVID-19-ASSOCIATED CONDITIONS [patent_app_type] => utility [patent_app_number] => 17/323901 [patent_app_country] => US [patent_app_date] => 2021-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22633 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17323901 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17850523 [patent_doc_number] => 20220280564 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => METHODS FOR EXPANDING T CELLS FOR THE TREATMENT OF CANCER AND RELATED MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 17/281095 [patent_app_country] => US [patent_app_date] => 2021-02-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27812 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17281095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17258541 [patent_doc_number] => 20210371526 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-02 [patent_title] => HOMODIMERIC BISPECIFIC ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/290651 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50147 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290651 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17342202 [patent_doc_number] => 20220008533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => COMPOSITION AND METHODS OF TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES [patent_app_type] => utility [patent_app_number] => 17/290527 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13150 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336076 [patent_doc_number] => 20220002407 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => HOMODIMER-TYPE BISPECIFIC ANTIBODY TARGETING CD19 AND CD3, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/290753 [patent_app_country] => US [patent_app_date] => 2019-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33800 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290753 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336100 [patent_doc_number] => 20220002431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => BISPECIFIC ANTIBODY BINDING TO CD20 AND CD3 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/290754 [patent_app_country] => US [patent_app_date] => 2019-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18205 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290754 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299501 [patent_doc_number] => 20210395340 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => IL4/IL13 Receptor Molecule for Veterinary Use [patent_app_type] => utility [patent_app_number] => 17/287756 [patent_app_country] => US [patent_app_date] => 2019-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18837 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17287756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17292245 [patent_doc_number] => 20210388084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-16 [patent_title] => ANTI-HUMAN CD89 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/288471 [patent_app_country] => US [patent_app_date] => 2019-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 44588 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214558 [patent_doc_number] => 20210347895 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => EXOSOME-TARGETING BISPECIFIC ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/283614 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283614 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17185260 [patent_doc_number] => 20210332145 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-28 [patent_title] => ANTI-BCMA ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/284371 [patent_app_country] => US [patent_app_date] => 2019-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17284371 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299542 [patent_doc_number] => 20210395381 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => TFR-SPECIFIC BINDING MOIETIES AND TRANSCYTOSIS METHOD TO SELECT VNARS THAT CROSS CELLULAR BARRIERS [patent_app_type] => utility [patent_app_number] => 17/275911 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22779 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275911 [rel_patent_id] =>[rel_patent_doc_number] =>)